General Information of the Protein
Protein ID |
PT01170
|
||||
---|---|---|---|---|---|
Protein Name |
DNA topoisomerase 1
|
||||
Secondarily Protein Name |
DNA topoisomerase I
|
||||
Gene Name |
TOP1
|
||||
Sequence |
MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKKHKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEPEDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKDKDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKFYYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKCDFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGLFRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENIQGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALYFIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNKVPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQQLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLADARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSKLNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEF
Show/Hide
|
||||
Organism |
Homo sapiens, Human
|
||||
Protein Classification |
Enzyme
>
Isomerase
|
||||
Function |
Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter.
Show/Hide
|
||||
Uniprot ID |
Show/Hide
|
||||
Ensembl ID | |||||
HGNC ID | |||||
Subcellular Location |
Nucleus
Nucleolus
Nucleus
Nucleoplasm
|
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000018 , HL-60
Cell Line ID: CL000017 , HeLa
Cell Line ID: CL000083 , MCF-7
Cell Line ID: CL000013 , Sf9
Biochemical Assays
Clinical Information about the Protein
Target 1 ( DNA topoisomerase I (TOP1) )
Target Type | Successful Target | ||||
---|---|---|---|---|---|
Disease | 10 Target-related Diseases | 10 | |||
1 | Bacterial infection [ICD-11: 1A00-1C4Z] | ||||
2 | Colorectal cancer [ICD-11: 2B91.Z] | ||||
3 | Small-cell lung cancer [ICD-11: 2C25.Y] | ||||
4 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | ||||
5 | Gastric adenocarcinoma [ICD-11: 2B72] | ||||
6 | Human immunodeficiency virus infection [ICD-11: 1C62] | ||||
7 | Acquired immune deficiency syndrome [ICD-11: 1C62.3] | ||||
8 | Breast cancer [ICD-11: 2C60-2C65] | ||||
9 | Lymphoma [ICD-11: 2A80-2A86] | ||||
10 | Ovarian cancer [ICD-11: 2C73] | ||||
Approved Drug(s) | 4 Approved Drugs | 4 | |||
1 | B-Lactams | Approved | |||
2 | Irinotecan | Approved | |||
3 | Topetecan | Approved | |||
4 | Topotecan | Approved | |||
Clinical Trial Drug(s) | 13 Clinical Trial Drugs | 13 | |||
1 | Camptothecin | Phase 3 | |||
2 | Edotecarin | Phase 3 | |||
3 | Exatecan | Phase 3 | |||
4 | Rubitecan | Phase 3 | |||
5 | 9-AMINOCAMPTOTHECIN | Phase 2 | |||
6 | Beta-Lapachone | Phase 2 | |||
7 | CRLX101 | Phase 2 | |||
8 | DIFLOMOTECAN | Phase 2 | |||
9 | Gimatecan | Phase 2 | |||
10 | LE-SN38 | Phase 2 | |||
11 | Daniquidone | Phase 1 | |||
12 | LMP400 | Phase 1 | |||
13 | LMP744 | Phase 1 | |||
Discontinued Drug(s) | 3 Discontinued Drugs | 3 | |||
1 | Lurtotecan | Discontinued in Phase 2 | |||
2 | BE-13793C | Terminated | |||
3 | BN-80245 | Terminated |